These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33277847)

  • 21. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
    González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA
    Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a correlation between inflammatory markers and coagulation parameters in women with advanced ovarian endometriosis?
    Ding S; Lin Q; Zhu T; Li T; Zhu L; Wang J; Zhang X
    BMC Womens Health; 2019 Dec; 19(1):169. PubMed ID: 31888633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
    Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
    J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
    Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
    Han L; Kuang L
    J BUON; 2019; 24(4):1544-1548. PubMed ID: 31646806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors.
    Vysotskii MM; Digaeva MA; Kushlinskii NE; Abbasova SG; Laktionov KP; Ermilova VD; Bakhoeva KA; Kryuk YV; Manukhin IB
    Bull Exp Biol Med; 2009 Nov; 148(5):810-4. PubMed ID: 20396799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
    Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer.
    Duan Y; Cui C; Qiu C; Sun G; Wang X; Wang P; Ye H; Dai L; Shi J
    Dis Markers; 2022; 2022():6657820. PubMed ID: 35273656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies.
    Dehaven K; Taylor DD; Gercel-Taylor C
    Int J Gynecol Cancer; 2002; 12(6):715-9. PubMed ID: 12445248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The vascular endothelial growth factor in patients with advanced ovarian cancer on the background of chemotherapy according to the AP scheme.].
    Abakumova TV; Gening SO; Dolgova DR; Gening TP; Antoneeva II; Poludnyakova LV; Kuznetsova TI; Dergunova YA; Panchenko EG
    Klin Lab Diagn; 2018; 63(9):543-548. PubMed ID: 30735319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.